Cannabix Technologies Makes Advances with Marijuana Breathalyzer Development and Renews Research with Yost Group
29 May 2019 - 10:35PM
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the
“Company or Cannabix”) developer of the Cannabix Marijuana
Breathalyzer for law enforcement and the workplace, is pleased to
report that Company engineers have made a significant breakthrough
with the ionization module which is a vital component of the
breathalyzer device, where breath samples are ionized prior to
entrance into the FAIMS cell. New ion focussing techniques have
resulted in a 30% increase in ion current and transmission/signal
strength in testing, further increasing instrument sensitivity. The
Company also reports that it has been steadily progressing with
human breath testing at its Vancouver, BC, based lab with its FAIMS
(field asymmetric waveform ion mobility spectrometry)
∆9-tetrahydrocannabinol (“THC”) detection device and breath
collection unit (“BCU”). Testing and refinement of the BCU over the
last 30 days has led to upgrades in flow and CO2 sensor components
as well as refinements in breath analysis from various users.
Furthermore, engineers are developing an improved detector
component for the system and a smaller footprint for the ionization
chamber. These upgrades are being made in preparation for a design
freeze of the prototype and multi device creation for additional
testing. The Company is also preparing new marketing materials of
its device for potential pilot users.
The Company is also pleased to report that it has renewed its
ongoing research engagement with the Dr. Rick Yost group at the
University of Florida (UF). Research at UF is done in parallel with
Cannabix research team in Canada and Gainesville to advance complex
development of breath testing devices using ion mobility. The Yost
Research Group is a world leader and pioneer in the development of
FAIMS, and Cannabix and the Yost Research Group are working
together to identify THC in ultra low ranges using highly sensitive
FAIMS and FAIMS-mass spectrometer systems.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer
development for law enforcement and the workplace. Cannabix has
established breath testing technologies in the pursuit of bringing
durable, portable hand-held tools to market to enhance detection of
marijuana impaired driving offences on roads at a time when
marijuana is becoming legal in many global jurisdictions. Cannabix
is working to develop drug-testing devices that will detect THC-
the psychoactive component of marijuana that causes intoxication-
using breath samples. In particular, Cannabix is focused on
developing breath testing devices for detection of recent use of
THC, in contrast to urine testing for THC metabolite that requires
an invasive collection and reflects previous usage from days or
even weeks earlier. The devices will also be useful for other
practical applications such as testing employees in the workplace
where impairment by THC can be hazardous.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEOCannabix Technologies Inc.
For further information, contact the Company at
info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements This
press release contains forward-looking information that involves
various risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company’s plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing “patent pending” technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Oct 2023 to Oct 2024